Highlights in Metastatic Breast Cancer From the 2023 San Antonio Breast Cancer Symposium

A Review of Selected Presentations From SABCS 2023 December 5-9, 2023 • San Antonio, Texas Clinical Outcomes by Age Subgroups in the Phase 3 TROPiCS-02 […]

Sequencing Therapies: Optimal Treatment for HR+/HER2– Metastatic Breast Cancer

H&O What are the options for first-line treatment of patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer? VK The […]

Addressing Unmet Need in the Management of Patients With ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer: Clinician’s Perspective

Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]